8-K: Vivos Therapeutics Announces New Equity Incentive Plan and Amended Executive Employment Agreements

Vivos Therapeutics has approved a new equity incentive plan and amended employment agreements for its CEO and CFO, pending stockholder approval.

Summary

• Vivos Therapeutics' Board of Directors has approved the 2024 Omnibus Equity Incentive Plan, which will replace the 2019 plan, subject to stockholder approval.
• The new plan will make 1,600,000 shares of common stock available for future awards.
• The company has also approved contingent stock option awards totaling 1,020,487 options to executives and other employees, with an exercise price of $2.62 per share.
• Amended employment agreements for the CEO and CFO include increased base salaries to $450,000 and $320,000 respectively, and target annual bonuses of 75% and 50% of their base salaries.
• The amended agreements also outline severance benefits, including up to 24 months of base salary in the event of a change in control.

Sentiment

Score: 7

Explanation: The document outlines positive changes in executive compensation and a new equity plan, which are generally viewed favorably by investors. However, the plan is subject to stockholder approval, which introduces some uncertainty.

Positives

• The new equity incentive plan aims to align the interests of employees and stockholders.
• The increased base salaries and bonus targets for the CEO and CFO may attract and retain talent.
• The severance benefits provide security for executives in the event of termination or a change in control.
• The new plan will allow the company to operate for several years.

Negatives

• The new equity plan is subject to stockholder approval, and if not approved, the 2019 plan will remain in place.
• The contingent stock options will be null and void if the stockholders do not approve the 2024 Omnibus Plan.

Risks

• Stockholder approval of the 2024 Omnibus Plan is not guaranteed.
• The company's ability to operate the 2024 Omnibus Plan for several years is subject to change based on factors such as merger and acquisition activity.
• The new employment agreements include restrictive covenants that could limit the executives' future employment options.

Future Outlook

The company anticipates that the 1,600,000 shares of Common Stock will allow the 2024 Omnibus Plan to operate for several years, although this could change based on other factors. The new employment agreements will take effect on January 1, 2025.

Management Comments

• The purpose of the 2024 Omnibus Plan is to promote the success and enhance the value of the Company by linking the personal interest of the participants to those of the Company's stockholders by providing the participants with an incentive for outstanding performance.

Industry Context

The implementation of equity incentive plans and revised executive compensation packages is a common practice in the corporate world to attract, retain, and motivate key personnel. These changes are often benchmarked against industry standards to ensure competitiveness.

Comparison to Industry Standards

• The use of omnibus equity incentive plans is a common practice among publicly traded companies, such as those in the biotechnology and medical device sectors, to align employee and shareholder interests.
• The base salary increases for the CEO and CFO are likely benchmarked against similar roles in comparable companies, such as those with similar market capitalization and revenue.
• The severance packages, including the 24-month base salary in the event of a change in control, are also common in executive employment agreements, similar to those seen in companies like Align Technology and InMode.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the new equity plan, but also by the potential for increased performance from incentivized employees.
• Employees, particularly executives, will benefit from the new equity plan and increased compensation.
• The changes are not expected to have a direct impact on customers, suppliers, or creditors.

Next Steps

• The company will seek stockholder approval for the 2024 Omnibus Plan at the 2024 Annual Meeting of Stockholders.
• The company will file the full text of the 2024 Omnibus Plan and the Amended Employment Agreements as an exhibit to its Quarterly Report on Form 10-Q for the period ended September 30, 2024.
• The amended employment agreements for the CEO and CFO will take effect on January 1, 2025.

Key Dates

Keywords

equity incentive plan, stock options, executive compensation, employment agreements, severance, Vivos Therapeutics, stockholder approval